US Patent Issued to Boehringer Ingelheim International on Aug. 26 for "Heterobicyclic amides as inhibitors of CD38" (Massachusetts Inventors)

ALEXANDRIA, Va., Aug. 26 -- United States Patent no. 12,398,146, issued on Aug. 26, was assigned to Boehringer Ingelheim International GmbH (Ingelheim, Germany).

"Heterobicyclic amides as inhibitors of CD38" was invented by Laurie B. Schenkel (Cambridge, Mass.), Melissa Marie Vasbinder (Cambridge, Mass.), Kevin Wayne Kuntz (Cambridge, Mass.), Nicholas Robert Perl (Cambridge, Mass.) and Jennifer Downing (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer."

The patent was filed on April 18, 2024, under Application No. 18/638,989.

*For further informa...